Laurie Harden
Psychiatry · Tallahassee, FLNPI 1952500118
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 272 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations.
Across 272 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$523
- Johnson & Johnson$393
- Takeda Pharmaceuticals U.S.A., Inc.$375
- Supernus Pharmaceuticals, Inc.$304
- Otsuka America Pharmaceutical, Inc.$286
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,80199%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 77 | $1,109 |
| Teva Pharmaceuticals USA, Inc. | 29 | $523 |
| Johnson & Johnson | 19 | $393 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $375 |
| Supernus Pharmaceuticals, Inc. | 12 | $304 |
| Otsuka America Pharmaceutical, Inc. | 15 | $286 |
| Vanda Pharmaceuticals Inc. | 14 | $279 |
| Neurocrine Biosciences, Inc. | 10 | $229 |
| Lundbeck LLC | 12 | $224 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $196 |
| Alkermes, Inc. | 8 | $179 |
| Sunovion Pharmaceuticals Inc. | 10 | $149 |
| Tris Pharma Inc | 6 | $117 |
| Corium, LLC | 3 | $84 |
| Alfasigma USA, Inc. | 5 | $83 |
| Idorsia Pharmaceuticals US Inc | 4 | $79 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Bausch Health US, LLC | 2 | $32 |
| Adlon Therapeutics L.p. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| Merck | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,834 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 15 | $476 |
| Fluoxetine Hcl | 23 | $419 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $389 |
| Lamotrigine | 12 | $208 |
| Lithium Carbonate ErLithium Carbonate | 12 | $190 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Tallahassee
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
- Heather LuingSaint Augustine$1.5M
- Todd GatesWest Melbourne$1.2M
- Lawrence ReccoppaGainesville$968K
- Thomas ValenteLeesburg$967K
- Michelle ScargleClearwater$926K
- David SheehanTampa$631K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.